Kura Oncology (NASDAQ:KURA) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a buy rating in a report published on Wednesday.

KURA has been the topic of a number of other research reports. JMP Securities reissued a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a report on Thursday, February 6th. Wedbush reiterated an “outperform” rating and set a $36.00 price objective on shares of Kura Oncology in a research note on Thursday, February 27th. UBS Group cut their target price on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Cantor Fitzgerald raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Scotiabank lowered their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Stock Performance

Shares of KURA stock opened at $7.05 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a market cap of $569.32 million, a price-to-earnings ratio of -2.99 and a beta of 0.85. Kura Oncology has a 52 week low of $6.79 and a 52 week high of $23.48. The firm’s 50-day simple moving average is $7.82 and its two-hundred day simple moving average is $12.05.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. As a group, equities analysts forecast that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Buying and Selling

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,729 shares of company stock worth $92,307. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

A number of large investors have recently modified their holdings of the company. RA Capital Management L.P. bought a new position in Kura Oncology during the fourth quarter valued at approximately $38,769,000. Millennium Management LLC boosted its stake in shares of Kura Oncology by 180.1% in the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock valued at $20,618,000 after purchasing an additional 1,521,954 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Kura Oncology in the 4th quarter valued at $8,518,000. Marshall Wace LLP bought a new position in shares of Kura Oncology during the 4th quarter valued at $8,265,000. Finally, D. E. Shaw & Co. Inc. raised its position in Kura Oncology by 172.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,151,195 shares of the company’s stock worth $10,027,000 after purchasing an additional 727,987 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.